​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $144.43, with a high of $160.00 and a low of $120.00. This represents a 58.89% increase from the last price of $90.90.

$80 $96 $112 $128 $144 $160 High: $160 Avg: $144.43 Low: $120 Last Closed Price: $90.9

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 22 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals58.89%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2522
Avg Price Target$144.50$144.60$141.55
Last Closing Price$90.90$90.90$90.90
Upside/Downside58.97%59.08%55.72%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 265112--18
Sep, 265102--17
Aug, 265101--16
Jul, 264111--16
Jun, 264111--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Raghuram SelvarajuH.C. Wainwright$130.00$90.7843.20%43.01%
Oct 08, 2026Lisa WalterRBC Capital$159.00$87.6981.32%74.92%
Aug 28, 2026David HoangDeutsche Bank$120.00$112.536.64%32.01%
Aug 05, 2026Canaccord Genuity$154.00$105.7845.59%69.42%
Aug 05, 2026National Bank$160.00$105.7851.26%76.02%
Jul 07, 2026RBC Capital$141.00$111.6826.25%55.12%
Jun 16, 2026Whitney IjemCanaccord Genuity$151.00$89.7068.34%66.12%
Jun 15, 2026Paul MatteisStifel Nicolaus$133.00$94.7340.40%46.31%
Jun 15, 2026Wells Fargo$155.00$88.3875.38%70.52%
May 07, 2026Canaccord Genuity$143.00$96.6148.02%57.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026William BlairOutperforminitialise
Oct 12, 2026H.C. WainwrightBuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 17, 2026Wolfe ResearchOutperforminitialise
Aug 28, 2026Deutsche BankHoldinitialise
Aug 05, 2026CitigroupBuyBuyhold
Aug 05, 2026CitigroupOutperformOutperformhold
Aug 05, 2026CitigroupMarket OutperformMarket Outperformhold
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 17, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-3.51$-3.20$-4.34$-3.11---
Avg Forecast$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-5.52%-0.57%-5.34%26.42%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.15M$23.64M$77.43M$130.13M$189.76M---
Avg Forecast$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %4.19%10.43%-1.75%3.27%4.35%---

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-69.61M$-181.12M$-184.68M$-260.60M$-201.92M---
Avg Forecast$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-16.57%-11.12%-10.02%46.86%---

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 22 Wall Street analysts, averages $144.43 over the next 12 months. The price target range spans from $120 at the low end to $160 at the high end, suggesting a potential 58.89% change from the previous closing price of $90.9.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 58.89% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • October 2026: 27.78% Strong Buy, 61.11% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 29.41% Strong Buy, 58.82% Buy, 11.76% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.75, marking a -75.88% decrease from the reported $-3.11 in 2025. Estimates for the following years are $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $333.83M, reflecting a 75.92% increase from the reported $189.76M in 2025. The forecast for 2027 is $602.63M, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-42.973M, representing a -78.72% decrease from the reported $-202M in 2025. Projections indicate $114.18M in 2027, and $362.02M in 2028.